NCT02310906: A trial that was reported late by Sarepta Therapeutics, Inc.
This trial has reported, although it was 168 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02310906 |
|---|---|
| Title | A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of SRP-4053 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 13, 2015 |
| Completion date | March 25, 2019 |
| Required reporting date | March 24, 2020, midnight |
| Actual reporting date | Sept. 9, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 168 |